Global Vendor Neutral Archive (VNA) & PACS Market: By Modality, By Deployment, By Product Type, By Vendor Type, By Application, By End-User, By Region & Segmental Insights Trends and Forecast, 2024 – 2034

  • Industry: Healthcare
  • Report ID: TNR-110-1087
  • Number of Pages: 420
  • Table/Charts : Yes
  • May, 2024
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10015
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Vendor Neutral Archive (VNA) and Picture Archiving and Communication System (PACS) are both integral components of medical imaging informatics, playing crucial roles in managing, storing, and accessing medical images and associated patient data within healthcare organizations. PACS primarily focuses on the acquisition, storage, retrieval, distribution, and display of medical images generated from various imaging modalities, such as X-ray, MRI, CT scans, ultrasound, and more. It is typically used within radiology departments for diagnostic interpretation and clinical decision-making. VNA, on the other hand, is designed to serve as a central repository for storing and managing medical images and related data from multiple imaging modalities and departments across the entire healthcare enterprise. It aims to address issues of data silos, interoperability, and long-term data retention, offering a vendor-agnostic platform for archiving images and ensuring data accessibility and integrity. Integration of AI algorithms and advanced analytics capabilities into VNA and PACS platforms is enhancing diagnostic capabilities, clinical decision-making, and workflow efficiency. AI-powered tools for image analysis, interpretation, and triaging are being integrated with VNA and PACS solutions to automate routine tasks, accelerate image processing, and improve diagnostic accuracy and efficiency. In terms of revenue, the global vendor neutral archive (VNA) & PACS market was worth US$ 4.4 Bn in 2023, anticipated to witness CAGR of 9.8% during 2024 – 2034.

Global Vendor Neutral Archive (VNA) & PACS Market Revenue & Forecast, (US$ Million), 2016 – 2034

Global Vendor Neutral Archive (VNA) & PACS Market Trends and Insights

Growing Volume and Complexity of Medical Imaging Data: The proliferation of medical imaging modalities, such as MRI, CT, ultrasound, and digital radiography, has led to a significant increase in the volume and complexity of medical imaging data. VNA and PACS solutions are equipped to handle large datasets and diverse image formats while ensuring efficient storage, retrieval, and management of medical images, diagnostic reports, and associated patient information.

Increasing Adoption of Enterprise Imaging Solutions: Healthcare organizations are increasingly adopting enterprise imaging strategies to consolidate and manage medical imaging data from multiple departments, modalities, and locations. VNA and PACS solutions play a crucial role in these strategies by providing a centralized repository for storing, accessing, and sharing medical images and associated patient data across the enterprise.

Advancements in Cloud-based Imaging Solutions: Cloud-based VNA and PACS solutions are gaining traction due to their scalability, flexibility, and cost-effectiveness. Cloud deployment offers healthcare providers the ability to store and access medical imaging data securely, offload IT infrastructure management, and support remote access and collaboration. Additionally, cloud-based VNA and PACS solutions enable seamless integration with other cloud-based healthcare applications and services.

Vendor Neutral Archive (VNA) has Garnered Major Market Share in the Global Vendor Neutral Archive (VNA) & PACS Market in 2023

The demand for Vendor Neutral Archive (VNA) solutions is primarily driven by several factors that contribute to the efficient management, storage, and accessibility of medical imaging data across healthcare organizations. Healthcare institutions often accumulate vast amounts of medical imaging data from multiple modalities, departments, and facilities. VNA solutions enable the consolidation of diverse image formats and data sources into a centralized repository, promoting interoperability and seamless access to patient information across the enterprise. With the exponential growth of medical imaging data, healthcare providers require scalable storage solutions capable of accommodating large datasets while optimizing storage utilization. VNA platforms offer scalable storage architectures and advanced data compression techniques to manage growing volumes of images efficiently.

By Application Cardiology and Radiology Segment had the Highest Share in the Global Vendor Neutral Archive (VNA) & PACS Market in 2023.

Cardiology and Radiology segment dominated the global Vendor Neutral Archive (VNA) & PACS market, in terms of revenue and is estimated to sustain its dominance over the forecast period. Cardiologists require high-quality imaging studies to accurately diagnose various cardiac conditions, assess cardiac function, and plan appropriate treatment strategies. VNA & PACS solutions support interventional cardiology procedures by providing access to pre-procedural imaging studies, guiding catheter-based interventions, and facilitating post-procedure assessment. Radiology is one of the largest users of medical imaging technology, encompassing various modalities such as X-ray, MRI, CT, ultrasound, and nuclear medicine. Radiologists rely on advanced visualization tools, diagnostic workstations, and decision support systems integrated into PACS for image interpretation and diagnosis.

By End User Hospitals & Clinics had the Highest Share in the Global Vendor Neutral Archive (VNA) & PACS Market in 2023.

Hospitals and clinics are increasingly transitioning from traditional film-based radiology systems to digital imaging solutions. VNA & PACS enable healthcare facilities to digitize, store, and manage medical images in electronic format, facilitating seamless integration with electronic health records (EHR) and other clinical systems. The volume of medical imaging data generated by hospitals and clinics continues to grow rapidly, driven by factors such as technological advancements in imaging modalities and increasing patient volumes. VNA & PACS solutions offer scalable, centralized storage and efficient image management capabilities, allowing healthcare providers to store, retrieve, and share large volumes of medical images across the organization. VNA & PACS solutions streamline clinical workflows within hospitals and clinics by providing radiologists and clinicians with instant access to patient imaging studies and related information. This enables faster diagnosis, treatment planning, and decision-making, leading to improved patient outcomes and satisfaction.

North America has garnered major market share in the vendor neutral archive (VNA) & PACS market in 2023. Healthcare facilities in North America are subject to stringent regulatory requirements regarding the storage, management, and security of patient health information, including medical images. VNA & PACS solutions help healthcare providers comply with regulations such as the Health Insurance Portability and Accountability Act (HIPAA) by providing secure, auditable storage and access controls for medical images. With the increasing complexity of healthcare delivery systems and the growing importance of care coordination, there is a strong demand for interoperable IT solutions that enable seamless data exchange across different healthcare settings and systems. VNA & PACS solutions facilitate interoperability by standardizing image formats, protocols, and interfaces, allowing healthcare organizations to share and access medical images from disparate sources and systems.

Competitive Landscape: Global Vendor Neutral Archive (VNA) & PACS Market:

  • Agfa Healthcare NV
  • Dell Technologies Inc.
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • IBM Corporation
  • Koninklijke Philips NV
  • Lexmark International Inc.
  • McKesson Corporation
  • Novarad Corporation
  • Siemens Healthineers AG
  • Other Industry Participants

Global Vendor Neutral Archive (VNA) & PACS Market: Key Takeaways 

Report Specifications Details
Market Revenue in 2023 US$ 4.4 Bn
Market Size Forecast by 2034 US$ 9.1 Bn
Growth Rate (CAGR) 9.8%
Historic Data 2016 – 2022
Base Year for Estimation 2023
Forecast Period 2024 – 2034
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Modality, By Deployment, By Product Type, By Vendor Type, By Application, By End-User
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players Agfa Healthcare NV,Dell Technologies Inc.,FUJIFILM Holdings Corporation,GE Healthcare,IBM Corporation,Koninklijke Philips NV,Lexmark International Inc.,McKesson Corporation,Novarad Corporation,Siemens Healthineers AG, Other Market Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free):  +81 663-386-8111

South Korea (Toll-Free):  +82-808- 703-126

Saudi Arabia (Toll-Free):  +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

Global Vendor Neutral Archive (VNA) & PACS Market Scope: 

By Modality

  • CT
  • Mammography
  • MRI
  • Ultrasound
  • X-Rays
  • PET

By Deployment

  • On-Premise
  • Cloud-Based
  • Hybrid Model

By Product Type

  • VNA
    • Department VNA
    • Multi-Department VNA
    • Multi-Site VNA
  • PACS
    • Department PACS
    • Multi-Department PACS
    • Multi-Site PACS

By Vendor Type

  • Independent Vendor
  • Third-party Vendor

By Application

  • Cardiology
  • Orthopedic
  • Oncology
  • Neurology
  • Obstetrics and Gynecology
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Report Layout

Table of Contents

.

1.Market Scope
1.1.Market Segmentation

1.2.Years Considered
1.2.1.Historic Years: 2016 – 2022

1.2.2.Base Year: 2023

1.2.3.Forecast Years: 2024 – 2034

2.Key Target Audiences

3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire

3.1.2.Global Percentage Breakdown

3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)

3.2.Secondary Research
3.2.1.Paid Databases

3.2.2.Secondary Sources

3.3.Market Size Estimates
3.3.1.Top-Down Approach

3.3.2.Bottom-Up Approach

3.4.Data Triangulation Methodology

3.5.Research Assumptions

4.Recommendations and Insights from TNR’s Perspective**

5.Holistic Overview of Vendor Neutral Archive (VNA) and PACS Market

6.Market Synopsis: Vendor Neutral Archive (VNA) and PACS Market

7.Vendor Neutral Archive (VNA) and PACS Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition

7.1.2.Industry Development

7.2.Market Dynamics
7.2.1.Drivers

7.2.2.Restraints

7.2.3.Opportunities

7.2.4.Challenges

7.3.Trends in Vendor Neutral Archive (VNA) and PACS Market

7.4.Market Determinants Radar Chart

7.5.Macro-Economic and Micro-Economic Indicators: Vendor Neutral Archive (VNA) and PACS Market

7.6.Porter’s Five Force Analysis

7.7.Impact of Covid-19 on Vendor Neutral Archive (VNA) and PACS Market

8.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
8.1.Overview
8.1.1.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)

8.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
8.2.1.CT
8.2.1.1.Definition

8.2.1.2.Market Estimation and Penetration, 2016 – 2023

8.2.1.3.Market Forecast, 2024 – 2034

8.2.1.4.Compound Annual Growth Rate (CAGR)

8.2.1.5.Regional Bifurcation
8.2.1.5.1.North America
8.2.1.5.1.1.Market Estimation, 2016 – 2023

8.2.1.5.1.2.Market Forecast, 2024 – 2034

8.2.1.5.2.Europe
8.2.1.5.2.1.Market Estimation, 2016 – 2023

8.2.1.5.2.2.Market Forecast, 2024 – 2034

8.2.1.5.3.Asia Pacific
8.2.1.5.3.1.Market Estimation, 2016 – 2023

8.2.1.5.3.2.Market Forecast, 2024 – 2034

8.2.1.5.4.Middle East and Africa
8.2.1.5.4.1.Market Estimation, 2016 – 2023

8.2.1.5.4.2.Market Forecast, 2024 – 2034

8.2.1.5.5.Latin America
8.2.1.5.5.1.Market Estimation, 2016 – 2023

8.2.1.5.5.2.Market Forecast, 2024 – 2034

8.2.2.Mammography
8.2.2.1.Definition

8.2.2.2.Market Estimation and Penetration, 2016 – 2023

8.2.2.3.Market Forecast, 2024 – 2034

8.2.2.4.Compound Annual Growth Rate (CAGR)

8.2.2.5.Regional Bifurcation
8.2.2.5.1.North America
8.2.2.5.1.1.Market Estimation, 2016 – 2023

8.2.2.5.1.2.Market Forecast, 2024 – 2034

8.2.2.5.2.Europe
8.2.2.5.2.1.Market Estimation, 2016 – 2023

8.2.2.5.2.2.Market Forecast, 2024 – 2034

8.2.2.5.3.Asia Pacific
8.2.2.5.3.1.Market Estimation, 2016 – 2023

8.2.2.5.3.2.Market Forecast, 2024 – 2034

8.2.2.5.4.Middle East and Africa
8.2.2.5.4.1.Market Estimation, 2016 – 2023

8.2.2.5.4.2.Market Forecast, 2024 – 2034

8.2.2.5.5.Latin America
8.2.2.5.5.1.Market Estimation, 2016 – 2023

8.2.2.5.5.2.Market Forecast, 2024 – 2034

8.2.3.MRI
8.2.3.1.Definition

8.2.3.2.Market Estimation and Penetration, 2016 – 2023

8.2.3.3.Market Forecast, 2024 – 2034

8.2.3.4.Compound Annual Growth Rate (CAGR)

8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2016 – 2023

8.2.3.5.1.2.Market Forecast, 2024 – 2034

8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2016 – 2023

8.2.3.5.2.2.Market Forecast, 2024 – 2034

8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2016 – 2023

8.2.3.5.3.2.Market Forecast, 2024 – 2034

8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2016 – 2023

8.2.3.5.4.2.Market Forecast, 2024 – 2034

8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2016 – 2023

8.2.3.5.5.2.Market Forecast, 2024 – 2034

8.2.4.Ultrasound
8.2.4.1.Definition

8.2.4.2.Market Estimation and Penetration, 2016 – 2023

8.2.4.3.Market Forecast, 2024 – 2034

8.2.4.4.Compound Annual Growth Rate (CAGR)

8.2.4.5.Regional Bifurcation
8.2.4.5.1.North America
8.2.4.5.1.1.Market Estimation, 2016 – 2023

8.2.4.5.1.2.Market Forecast, 2024 – 2034

8.2.4.5.2.Europe
8.2.4.5.2.1.Market Estimation, 2016 – 2023

8.2.4.5.2.2.Market Forecast, 2024 – 2034

8.2.4.5.3.Asia Pacific
8.2.4.5.3.1.Market Estimation, 2016 – 2023

8.2.4.5.3.2.Market Forecast, 2024 – 2034

8.2.4.5.4.Middle East and Africa
8.2.4.5.4.1.Market Estimation, 2016 – 2023

8.2.4.5.4.2.Market Forecast, 2024 – 2034

8.2.4.5.5.Latin America
8.2.4.5.5.1.Market Estimation, 2016 – 2023

8.2.4.5.5.2.Market Forecast, 2024 – 2034

8.2.5.X-Rays
8.2.5.1.Definition

8.2.5.2.Market Estimation and Penetration, 2016 – 2023

8.2.5.3.Market Forecast, 2024 – 2034

8.2.5.4.Compound Annual Growth Rate (CAGR)

8.2.5.5.Regional Bifurcation
8.2.5.5.1.North America
8.2.5.5.1.1.Market Estimation, 2016 – 2023

8.2.5.5.1.2.Market Forecast, 2024 – 2034

8.2.5.5.2.Europe
8.2.5.5.2.1.Market Estimation, 2016 – 2023

8.2.5.5.2.2.Market Forecast, 2024 – 2034

8.2.5.5.3.Asia Pacific
8.2.5.5.3.1.Market Estimation, 2016 – 2023

8.2.5.5.3.2.Market Forecast, 2024 – 2034

8.2.5.5.4.Middle East and Africa
8.2.5.5.4.1.Market Estimation, 2016 – 2023

8.2.5.5.4.2.Market Forecast, 2024 – 2034

8.2.5.5.5.Latin America
8.2.5.5.5.1.Market Estimation, 2016 – 2023

8.2.5.5.5.2.Market Forecast, 2024 – 2034

8.2.6.PET
8.2.6.1.Definition

8.2.6.2.Market Estimation and Penetration, 2016 – 2023

8.2.6.3.Market Forecast, 2024 – 2034

8.2.6.4.Compound Annual Growth Rate (CAGR)

8.2.6.5.Regional Bifurcation
8.2.6.5.1.North America
8.2.6.5.1.1.Market Estimation, 2016 – 2023

8.2.6.5.1.2.Market Forecast, 2024 – 2034

8.2.6.5.2.Europe
8.2.6.5.2.1.Market Estimation, 2016 – 2023

8.2.6.5.2.2.Market Forecast, 2024 – 2034

8.2.6.5.3.Asia Pacific
8.2.6.5.3.1.Market Estimation, 2016 – 2023

8.2.6.5.3.2.Market Forecast, 2024 – 2034

8.2.6.5.4.Middle East and Africa
8.2.6.5.4.1.Market Estimation, 2016 – 2023

8.2.6.5.4.2.Market Forecast, 2024 – 2034

8.2.6.5.5.Latin America
8.2.6.5.5.1.Market Estimation, 2016 – 2023

8.2.6.5.5.2.Market Forecast, 2024 – 2034

8.3.Key Segment for Channeling Investments
8.3.1.By Modality

9.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
9.1.Overview

9.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
9.2.1.Cloud
9.2.1.1.Definition

9.2.1.2.Market Estimation and Penetration, 2016 – 2023

9.2.1.3.Market Forecast, 2024 – 2034

9.2.1.4.Compound Annual Growth Rate (CAGR)

9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2016 – 2023

9.2.1.5.1.2.Market Forecast, 2024 – 2034

9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2016 – 2023

9.2.1.5.2.2.Market Forecast, 2024 – 2034

9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2016 – 2023

9.2.1.5.3.2.Market Forecast, 2024 – 2034

9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2016 – 2023

9.2.1.5.4.2.Market Forecast, 2024 – 2034

9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2016 – 2023

9.2.1.5.5.2.Market Forecast, 2024 – 2034

9.2.2.On-Premises
9.2.2.1.Definition

9.2.2.2.Market Estimation and Penetration, 2016 – 2023

9.2.2.3.Market Forecast, 2024 – 2034

9.2.2.4.Compound Annual Growth Rate (CAGR)

9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2016 – 2023

9.2.2.5.1.2.Market Forecast, 2024 – 2034

9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2016 – 2023

9.2.2.5.2.2.Market Forecast, 2024 – 2034

9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2016 – 2023

9.2.2.5.3.2.Market Forecast, 2024 – 2034

9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2016 – 2023

9.2.2.5.4.2.Market Forecast, 2024 – 2034

9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2016 – 2023

9.2.2.5.5.2.Market Forecast, 2024 – 2034

9.2.3.Hybrid
9.2.3.1.Definition

9.2.3.2.Market Estimation and Penetration, 2016 – 2023

9.2.3.3.Market Forecast, 2024 – 2034

9.2.3.4.Compound Annual Growth Rate (CAGR)

9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2016 – 2023

9.2.3.5.1.2.Market Forecast, 2024 – 2034

9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2016 – 2023

9.2.3.5.2.2.Market Forecast, 2024 – 2034

9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2016 – 2023

9.2.3.5.3.2.Market Forecast, 2024 – 2034

9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2016 – 2023

9.2.3.5.4.2.Market Forecast, 2024 – 2034

9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2016 – 2023

9.2.3.5.5.2.Market Forecast, 2024 – 2034

9.3.Key Segment for Channeling Investments
9.3.1.By Deployment

10.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
10.1.Overview

10.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
10.2.1.VNA (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Department VNA, Multi-Department VNA, Multi-Site VNA)
10.2.1.1.Department VNA

10.2.1.2.Multi-Department VNA

10.2.1.3.Multi-Site VNA

10.2.2.PACS (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Department PACS, Multi-Department PACS, Multi-Site PACS)
10.2.2.1.Department PACS

10.2.2.2.Multi-Department PACS

10.2.2.3.Multi-Site PACS

10.3.Key Segment for Channeling Investments
10.3.1.By Product Type

11.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
11.1.Overview

11.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
11.2.1.Independent Vendor
11.2.1.1.Definition

11.2.1.2.Market Estimation and Penetration, 2016 – 2023

11.2.1.3.Market Forecast, 2024 – 2034

11.2.1.4.Compound Annual Growth Rate (CAGR)

11.2.1.5.Regional Bifurcation
11.2.1.5.1.North America
11.2.1.5.1.1.Market Estimation, 2016 – 2023

11.2.1.5.1.2.Market Forecast, 2024 – 2034

11.2.1.5.2.Europe
11.2.1.5.2.1.Market Estimation, 2016 – 2023

11.2.1.5.2.2.Market Forecast, 2024 – 2034

11.2.1.5.3.Asia Pacific
11.2.1.5.3.1.Market Estimation, 2016 – 2023

11.2.1.5.3.2.Market Forecast, 2024 – 2034

11.2.1.5.4.Middle East and Africa
11.2.1.5.4.1.Market Estimation, 2016 – 2023

11.2.1.5.4.2.Market Forecast, 2024 – 2034

11.2.1.5.5.Latin America
11.2.1.5.5.1.Market Estimation, 2016 – 2023

11.2.1.5.5.2.Market Forecast, 2024 – 2034

11.2.2.Third-party Vendor
11.2.2.1.Definition

11.2.2.2.Market Estimation and Penetration, 2016 – 2023

11.2.2.3.Market Forecast, 2024 – 2034

11.2.2.4.Compound Annual Growth Rate (CAGR)

11.2.2.5.Regional Bifurcation
11.2.2.5.1.North America
11.2.2.5.1.1.Market Estimation, 2016 – 2023

11.2.2.5.1.2.Market Forecast, 2024 – 2034

11.2.2.5.2.Europe
11.2.2.5.2.1.Market Estimation, 2016 – 2023

11.2.2.5.2.2.Market Forecast, 2024 – 2034

11.2.2.5.3.Asia Pacific
11.2.2.5.3.1.Market Estimation, 2016 – 2023

11.2.2.5.3.2.Market Forecast, 2024 – 2034

11.2.2.5.4.Middle East and Africa
11.2.2.5.4.1.Market Estimation, 2016 – 2023

11.2.2.5.4.2.Market Forecast, 2024 – 2034

11.2.2.5.5.Latin America
11.2.2.5.5.1.Market Estimation, 2016 – 2023

11.2.2.5.5.2.Market Forecast, 2024 – 2034

11.3.Key Segment for Channeling Investments
11.3.1.By Vendor Type

12.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
12.1.Overview

12.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
12.2.1.Cardiology
12.2.1.1.Definition

12.2.1.2.Market Estimation and Penetration, 2016 – 2023

12.2.1.3.Market Forecast, 2024 – 2034

12.2.1.4.Compound Annual Growth Rate (CAGR)

12.2.1.5.Regional Bifurcation
12.2.1.5.1.North America
12.2.1.5.1.1.Market Estimation, 2016 – 2023

12.2.1.5.1.2.Market Forecast, 2024 – 2034

12.2.1.5.2.Europe
12.2.1.5.2.1.Market Estimation, 2016 – 2023

12.2.1.5.2.2.Market Forecast, 2024 – 2034

12.2.1.5.3.Asia Pacific
12.2.1.5.3.1.Market Estimation, 2016 – 2023

12.2.1.5.3.2.Market Forecast, 2024 – 2034

12.2.1.5.4.Middle East and Africa
12.2.1.5.4.1.Market Estimation, 2016 – 2023

12.2.1.5.4.2.Market Forecast, 2024 – 2034

12.2.1.5.5.Latin America
12.2.1.5.5.1.Market Estimation, 2016 – 2023

12.2.1.5.5.2.Market Forecast, 2024 – 2034

12.2.2.Orthopedic
12.2.2.1.Definition

12.2.2.2.Market Estimation and Penetration, 2016 – 2023

12.2.2.3.Market Forecast, 2024 – 2034

12.2.2.4.Compound Annual Growth Rate (CAGR)

12.2.2.5.Regional Bifurcation
12.2.2.5.1.North America
12.2.2.5.1.1.Market Estimation, 2016 – 2023

12.2.2.5.1.2.Market Forecast, 2024 – 2034

12.2.2.5.2.Europe
12.2.2.5.2.1.Market Estimation, 2016 – 2023

12.2.2.5.2.2.Market Forecast, 2024 – 2034

12.2.2.5.3.Asia Pacific
12.2.2.5.3.1.Market Estimation, 2016 – 2023

12.2.2.5.3.2.Market Forecast, 2024 – 2034

12.2.2.5.4.Middle East and Africa
12.2.2.5.4.1.Market Estimation, 2016 – 2023

12.2.2.5.4.2.Market Forecast, 2024 – 2034

12.2.2.5.5.Latin America
12.2.2.5.5.1.Market Estimation, 2016 – 2023

12.2.2.5.5.2.Market Forecast, 2024 – 2034

12.2.3.Oncology
12.2.3.1.Definition

12.2.3.2.Market Estimation and Penetration, 2016 – 2023

12.2.3.3.Market Forecast, 2024 – 2034

12.2.3.4.Compound Annual Growth Rate (CAGR)

12.2.3.5.Regional Bifurcation
12.2.3.5.1.North America
12.2.3.5.1.1.Market Estimation, 2016 – 2023

12.2.3.5.1.2.Market Forecast, 2024 – 2034

12.2.3.5.2.Europe
12.2.3.5.2.1.Market Estimation, 2016 – 2023

12.2.3.5.2.2.Market Forecast, 2024 – 2034

12.2.3.5.3.Asia Pacific
12.2.3.5.3.1.Market Estimation, 2016 – 2023

12.2.3.5.3.2.Market Forecast, 2024 – 2034

12.2.3.5.4.Middle East and Africa
12.2.3.5.4.1.Market Estimation, 2016 – 2023

12.2.3.5.4.2.Market Forecast, 2024 – 2034

12.2.3.5.5.Latin America
12.2.3.5.5.1.Market Estimation, 2016 – 2023

12.2.3.5.5.2.Market Forecast, 2024 – 2034

12.2.4.Neurology
12.2.4.1.Definition

12.2.4.2.Market Estimation and Penetration, 2016 – 2023

12.2.4.3.Market Forecast, 2024 – 2034

12.2.4.4.Compound Annual Growth Rate (CAGR)

12.2.4.5.Regional Bifurcation
12.2.4.5.1.North America
12.2.4.5.1.1.Market Estimation, 2016 – 2023

12.2.4.5.1.2.Market Forecast, 2024 – 2034

12.2.4.5.2.Europe
12.2.4.5.2.1.Market Estimation, 2016 – 2023

12.2.4.5.2.2.Market Forecast, 2024 – 2034

12.2.4.5.3.Asia Pacific
12.2.4.5.3.1.Market Estimation, 2016 – 2023

12.2.4.5.3.2.Market Forecast, 2024 – 2034

12.2.4.5.4.Middle East and Africa
12.2.4.5.4.1.Market Estimation, 2016 – 2023

12.2.4.5.4.2.Market Forecast, 2024 – 2034

12.2.4.5.5.Latin America
12.2.4.5.5.1.Market Estimation, 2016 – 2023

12.2.4.5.5.2.Market Forecast, 2024 – 2034

12.2.5.Obstetrics and Gynecology
12.2.5.1.Definition

12.2.5.2.Market Estimation and Penetration, 2016 – 2023

12.2.5.3.Market Forecast, 2024 – 2034

12.2.5.4.Compound Annual Growth Rate (CAGR)

12.2.5.5.Regional Bifurcation
12.2.5.5.1.North America
12.2.5.5.1.1.Market Estimation, 2016 – 2023

12.2.5.5.1.2.Market Forecast, 2024 – 2034

12.2.5.5.2.Europe
12.2.5.5.2.1.Market Estimation, 2016 – 2023

12.2.5.5.2.2.Market Forecast, 2024 – 2034

12.2.5.5.3.Asia Pacific
12.2.5.5.3.1.Market Estimation, 2016 – 2023

12.2.5.5.3.2.Market Forecast, 2024 – 2034

12.2.5.5.4.Middle East and Africa
12.2.5.5.4.1.Market Estimation, 2016 – 2023

12.2.5.5.4.2.Market Forecast, 2024 – 2034

12.2.5.5.5.Latin America
12.2.5.5.5.1.Market Estimation, 2016 – 2023

12.2.5.5.5.2.Market Forecast, 2024 – 2034

12.2.6.Others
12.2.6.1.Definition

12.2.6.2.Market Estimation and Penetration, 2016 – 2023

12.2.6.3.Market Forecast, 2024 – 2034

12.2.6.4.Compound Annual Growth Rate (CAGR)

12.2.6.5.Regional Bifurcation
12.2.6.5.1.North America
12.2.6.5.1.1.Market Estimation, 2016 – 2023

12.2.6.5.1.2.Market Forecast, 2024 – 2034

12.2.6.5.2.Europe
12.2.6.5.2.1.Market Estimation, 2016 – 2023

12.2.6.5.2.2.Market Forecast, 2024 – 2034

12.2.6.5.3.Asia Pacific
12.2.6.5.3.1.Market Estimation, 2016 – 2023

12.2.6.5.3.2.Market Forecast, 2024 – 2034

12.2.6.5.4.Middle East and Africa
12.2.6.5.4.1.Market Estimation, 2016 – 2023

12.2.6.5.4.2.Market Forecast, 2024 – 2034

12.2.6.5.5.Latin America
12.2.6.5.5.1.Market Estimation, 2016 – 2023

12.2.6.5.5.2.Market Forecast, 2024 – 2034

12.3.Key Segment for Channeling Investments
12.3.1.By Application

13.Global Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
13.1.Overview

13.2.Global Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
13.2.1.Hospitals and Clinics
13.2.1.1.Definition

13.2.1.2.Market Estimation and Penetration, 2016 – 2023

13.2.1.3.Market Forecast, 2024 – 2034

13.2.1.4.Compound Annual Growth Rate (CAGR)

13.2.1.5.Regional Bifurcation
13.2.1.5.1.North America
13.2.1.5.1.1.Market Estimation, 2016 – 2023

13.2.1.5.1.2.Market Forecast, 2024 – 2034

13.2.1.5.2.Europe
13.2.1.5.2.1.Market Estimation, 2016 – 2023

13.2.1.5.2.2.Market Forecast, 2024 – 2034

13.2.1.5.3.Asia Pacific
13.2.1.5.3.1.Market Estimation, 2016 – 2023

13.2.1.5.3.2.Market Forecast, 2024 – 2034

13.2.1.5.4.Middle East and Africa
13.2.1.5.4.1.Market Estimation, 2016 – 2023

13.2.1.5.4.2.Market Forecast, 2024 – 2034

13.2.1.5.5.Latin America
13.2.1.5.5.1.Market Estimation, 2016 – 2023

13.2.1.5.5.2.Market Forecast, 2024 – 2034

13.2.2.Diagnostic Centers
13.2.2.1.Definition

13.2.2.2.Market Estimation and Penetration, 2016 – 2023

13.2.2.3.Market Forecast, 2024 – 2034

13.2.2.4.Compound Annual Growth Rate (CAGR)

13.2.2.5.Regional Bifurcation
13.2.2.5.1.North America
13.2.2.5.1.1.Market Estimation, 2016 – 2023

13.2.2.5.1.2.Market Forecast, 2024 – 2034

13.2.2.5.2.Europe
13.2.2.5.2.1.Market Estimation, 2016 – 2023

13.2.2.5.2.2.Market Forecast, 2024 – 2034

13.2.2.5.3.Asia Pacific
13.2.2.5.3.1.Market Estimation, 2016 – 2023

13.2.2.5.3.2.Market Forecast, 2024 – 2034

13.2.2.5.4.Middle East and Africa
13.2.2.5.4.1.Market Estimation, 2016 – 2023

13.2.2.5.4.2.Market Forecast, 2024 – 2034

13.2.2.5.5.Latin America
13.2.2.5.5.1.Market Estimation, 2016 – 2023

13.2.2.5.5.2.Market Forecast, 2024 – 2034

13.2.3.Others
13.2.3.1.Definition

13.2.3.2.Market Estimation and Penetration, 2016 – 2023

13.2.3.3.Market Forecast, 2024 – 2034

13.2.3.4.Compound Annual Growth Rate (CAGR)

13.2.3.5.Regional Bifurcation
13.2.3.5.1.North America
13.2.3.5.1.1.Market Estimation, 2016 – 2023

13.2.3.5.1.2.Market Forecast, 2024 – 2034

13.2.3.5.2.Europe
13.2.3.5.2.1.Market Estimation, 2016 – 2023

13.2.3.5.2.2.Market Forecast, 2024 – 2034

13.2.3.5.3.Asia Pacific
13.2.3.5.3.1.Market Estimation, 2016 – 2023

13.2.3.5.3.2.Market Forecast, 2024 – 2034

13.2.3.5.4.Middle East and Africa
13.2.3.5.4.1.Market Estimation, 2016 – 2023

13.2.3.5.4.2.Market Forecast, 2024 – 2034

13.2.3.5.5.Latin America
13.2.3.5.5.1.Market Estimation, 2016 – 2023

13.2.3.5.5.2.Market Forecast, 2024 – 2034

13.3.Key Segment for Channeling Investments
13.3.1.By End User

14.North America Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
14.1.Overview
14.1.1.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)

14.2.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.2.1.CT

14.2.2.Mammography

14.2.3.MRI

14.2.4.Ultrasound

14.2.5.X-Rays

14.2.6.PET

14.3.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.3.1.Cloud

14.3.2.On-Premises

14.3.3.Hybrid

14.4.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.4.1.VNA
14.4.1.1.Department VNA

14.4.1.2.Multi-Department VNA

14.4.1.3.Multi-Site VNA

14.4.2.PACS
14.4.2.1.Department PACS

14.4.2.2.Multi-Department PACS

14.4.2.3.Multi-Site PACS

14.5.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.5.1.Independent Vendor

14.5.2.Third-party Vendor

14.6.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.Cardiology

14.6.2.Orthopedic

14.6.3.Oncology

14.6.4.Neurology

14.6.5.Obstetrics and Gynecology

14.6.6.Others

14.7.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.7.1.Hospitals and Clinics

14.7.2.Diagnostic Centers

14.7.3.Others

14.8.North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
14.8.1.U.S
14.8.1.1.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.8.1.1.1.CT

14.8.1.1.2.Mammography

14.8.1.1.3.MRI

14.8.1.1.4.Ultrasound

14.8.1.1.5.X-Rays

14.8.1.1.6.PET

14.8.1.2.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.8.1.2.1.Cloud

14.8.1.2.2.On-Premises

14.8.1.2.3.Hybrid

14.8.1.3.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.8.1.3.1.VNA
14.8.1.3.1.1.Department VNA

14.8.1.3.1.2.Multi-Department VNA

14.8.1.3.1.3.Multi-Site VNA

14.8.1.3.2.PACS
14.8.1.3.2.1.Department PACS

14.8.1.3.2.2.Multi-Department PACS

14.8.1.3.2.3.Multi-Site PACS

14.8.1.4.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.8.1.4.1.Independent Vendor

14.8.1.4.2.Third-party Vendor

14.8.1.5.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.8.1.5.1.Cardiology

14.8.1.5.2.Orthopedic

14.8.1.5.3.Oncology

14.8.1.5.4.Neurology

14.8.1.5.5.Obstetrics and Gynecology

14.8.1.5.6.Others

14.8.1.6.U.S Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.8.1.6.1.Hospitals and Clinics

14.8.1.6.2.Diagnostic Centers

14.8.1.6.3.Others

14.8.2.Canada
14.8.2.1.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.8.2.1.1.CT

14.8.2.1.2.Mammography

14.8.2.1.3.MRI

14.8.2.1.4.Ultrasound

14.8.2.1.5.X-Rays

14.8.2.1.6.PET

14.8.2.2.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.8.2.2.1.Cloud

14.8.2.2.2.On-Premises

14.8.2.2.3.Hybrid

14.8.2.3.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.8.2.3.1.VNA
14.8.2.3.1.1.Department VNA

14.8.2.3.1.2.Multi-Department VNA

14.8.2.3.1.3.Multi-Site VNA

14.8.2.3.2.PACS
14.8.2.3.2.1.Department PACS

14.8.2.3.2.2.Multi-Department PACS

14.8.2.3.2.3.Multi-Site PACS

14.8.2.4.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.8.2.4.1.Independent Vendor

14.8.2.4.2.Third-party Vendor

14.8.2.5.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.8.2.5.1.Cardiology

14.8.2.5.2.Orthopedic

14.8.2.5.3.Oncology

14.8.2.5.4.Neurology

14.8.2.5.5.Obstetrics and Gynecology

14.8.2.5.6.Others

14.8.2.6.Canada Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.8.2.6.1.Hospitals and Clinics

14.8.2.6.2.Diagnostic Centers

14.8.2.6.3.Others

14.8.3.Mexico
14.8.3.1.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.8.3.1.1.CT

14.8.3.1.2.Mammography

14.8.3.1.3.MRI

14.8.3.1.4.Ultrasound

14.8.3.1.5.X-Rays

14.8.3.1.6.PET

14.8.3.2.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.8.3.2.1.Cloud

14.8.3.2.2.On-Premises

14.8.3.2.3.Hybrid

14.8.3.3.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.8.3.3.1.VNA
14.8.3.3.1.1.Department VNA

14.8.3.3.1.2.Multi-Department VNA

14.8.3.3.1.3.Multi-Site VNA

14.8.3.3.2.PACS
14.8.3.3.2.1.Department PACS

14.8.3.3.2.2.Multi-Department PACS

14.8.3.3.2.3.Multi-Site PACS

14.8.3.4.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.8.3.4.1.Independent Vendor

14.8.3.4.2.Third-party Vendor

14.8.3.5.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.8.3.5.1.Cardiology

14.8.3.5.2.Orthopedic

14.8.3.5.3.Oncology

14.8.3.5.4.Neurology

14.8.3.5.5.Obstetrics and Gynecology

14.8.3.5.6.Others

14.8.3.6.Mexico Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.8.3.6.1.Hospitals and Clinics

14.8.3.6.2.Diagnostic Centers

14.8.3.6.3.Others

14.8.4.Rest of North America
14.8.4.1.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
14.8.4.1.1.CT

14.8.4.1.2.Mammography

14.8.4.1.3.MRI

14.8.4.1.4.Ultrasound

14.8.4.1.5.X-Rays

14.8.4.1.6.PET

14.8.4.2.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
14.8.4.2.1.Cloud

14.8.4.2.2.On-Premises

14.8.4.2.3.Hybrid

14.8.4.3.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
14.8.4.3.1.VNA
14.8.4.3.1.1.Department VNA

14.8.4.3.1.2.Multi-Department VNA

14.8.4.3.1.3.Multi-Site VNA

14.8.4.3.2.PACS
14.8.4.3.2.1.Department PACS

14.8.4.3.2.2.Multi-Department PACS

14.8.4.3.2.3.Multi-Site PACS

14.8.4.4.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
14.8.4.4.1.Independent Vendor

14.8.4.4.2.Third-party Vendor

14.8.4.5.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
14.8.4.5.1.Cardiology

14.8.4.5.2.Orthopedic

14.8.4.5.3.Oncology

14.8.4.5.4.Neurology

14.8.4.5.5.Obstetrics and Gynecology

14.8.4.5.6.Others

14.8.4.6.Rest of North America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
14.8.4.6.1.Hospitals and Clinics

14.8.4.6.2.Diagnostic Centers

14.8.4.6.3.Others

14.9.Key Segment for Channeling Investments
14.9.1.By Country

14.9.2.By Modality

14.9.3.By Deployment

14.9.4.By Product Type

14.9.5.By Vendor Type

14.9.6.By Application

14.9.7.By End User

15.Europe Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
15.1.Overview
15.1.1.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)

15.2.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.2.1.CT

15.2.2.Mammography

15.2.3.MRI

15.2.4.Ultrasound

15.2.5.X-Rays

15.2.6.PET

15.3.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.3.1.Cloud

15.3.2.On-Premises

15.3.3.Hybrid

15.4.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.4.1.VNA
15.4.1.1.Department VNA

15.4.1.2.Multi-Department VNA

15.4.1.3.Multi-Site VNA

15.4.2.PACS
15.4.2.1.Department PACS

15.4.2.2.Multi-Department PACS

15.4.2.3.Multi-Site PACS

15.5.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.5.1.Independent Vendor

15.5.2.Third-party Vendor

15.6.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.6.1.Cardiology

15.6.2.Orthopedic

15.6.3.Oncology

15.6.4.Neurology

15.6.5.Obstetrics and Gynecology

15.6.6.Others

15.7.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.7.1.Hospitals and Clinics

15.7.2.Diagnostic Centers

15.7.3.Others

15.8.Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
15.8.1.France
15.8.1.1.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.1.1.1.CT

15.8.1.1.2.Mammography

15.8.1.1.3.MRI

15.8.1.1.4.Ultrasound

15.8.1.1.5.X-Rays

15.8.1.1.6.PET

15.8.1.2.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.1.2.1.Cloud

15.8.1.2.2.On-Premises

15.8.1.2.3.Hybrid

15.8.1.3.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.1.3.1.VNA
15.8.1.3.1.1.Department VNA

15.8.1.3.1.2.Multi-Department VNA

15.8.1.3.1.3.Multi-Site VNA

15.8.1.3.2.PACS
15.8.1.3.2.1.Department PACS

15.8.1.3.2.2.Multi-Department PACS

15.8.1.3.2.3.Multi-Site PACS

15.8.1.4.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.1.4.1.Independent Vendor

15.8.1.4.2.Third-party Vendor

15.8.1.5.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.1.5.1.Cardiology

15.8.1.5.2.Orthopedic

15.8.1.5.3.Oncology

15.8.1.5.4.Neurology

15.8.1.5.5.Obstetrics and Gynecology

15.8.1.5.6.Others

15.8.1.6.France Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.1.6.1.Hospitals and Clinics

15.8.1.6.2.Diagnostic Centers

15.8.1.6.3.Others

15.8.2.The UK
15.8.2.1.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.2.1.1.CT

15.8.2.1.2.Mammography

15.8.2.1.3.MRI

15.8.2.1.4.Ultrasound

15.8.2.1.5.X-Rays

15.8.2.1.6.PET

15.8.2.2.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.2.2.1.Cloud

15.8.2.2.2.On-Premises

15.8.2.2.3.Hybrid

15.8.2.3.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.2.3.1.VNA
15.8.2.3.1.1.Department VNA

15.8.2.3.1.2.Multi-Department VNA

15.8.2.3.1.3.Multi-Site VNA

15.8.2.3.2.PACS
15.8.2.3.2.1.Department PACS

15.8.2.3.2.2.Multi-Department PACS

15.8.2.3.2.3.Multi-Site PACS

15.8.2.4.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.2.4.1.Independent Vendor

15.8.2.4.2.Third-party Vendor

15.8.2.5.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.2.5.1.Cardiology

15.8.2.5.2.Orthopedic

15.8.2.5.3.Oncology

15.8.2.5.4.Neurology

15.8.2.5.5.Obstetrics and Gynecology

15.8.2.5.6.Others

15.8.2.6.The UK Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.2.6.1.Hospitals and Clinics

15.8.2.6.2.Diagnostic Centers

15.8.2.6.3.Others

15.8.3.Spain
15.8.3.1.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.3.1.1.CT

15.8.3.1.2.Mammography

15.8.3.1.3.MRI

15.8.3.1.4.Ultrasound

15.8.3.1.5.X-Rays

15.8.3.1.6.PET

15.8.3.2.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.3.2.1.Cloud

15.8.3.2.2.On-Premises

15.8.3.2.3.Hybrid

15.8.3.3.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.3.3.1.VNA
15.8.3.3.1.1.Department VNA

15.8.3.3.1.2.Multi-Department VNA

15.8.3.3.1.3.Multi-Site VNA

15.8.3.3.2.PACS
15.8.3.3.2.1.Department PACS

15.8.3.3.2.2.Multi-Department PACS

15.8.3.3.2.3.Multi-Site PACS

15.8.3.4.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.3.4.1.Independent Vendor

15.8.3.4.2.Third-party Vendor

15.8.3.5.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.3.5.1.Cardiology

15.8.3.5.2.Orthopedic

15.8.3.5.3.Oncology

15.8.3.5.4.Neurology

15.8.3.5.5.Obstetrics and Gynecology

15.8.3.5.6.Others

15.8.3.6.Spain Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.3.6.1.Hospitals and Clinics

15.8.3.6.2.Diagnostic Centers

15.8.3.6.3.Others

15.8.4.Germany
15.8.4.1.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.4.1.1.CT

15.8.4.1.2.Mammography

15.8.4.1.3.MRI

15.8.4.1.4.Ultrasound

15.8.4.1.5.X-Rays

15.8.4.1.6.PET

15.8.4.2.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.4.2.1.Cloud

15.8.4.2.2.On-Premises

15.8.4.2.3.Hybrid

15.8.4.3.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.4.3.1.VNA
15.8.4.3.1.1.Department VNA

15.8.4.3.1.2.Multi-Department VNA

15.8.4.3.1.3.Multi-Site VNA

15.8.4.3.2.PACS
15.8.4.3.2.1.Department PACS

15.8.4.3.2.2.Multi-Department PACS

15.8.4.3.2.3.Multi-Site PACS

15.8.4.4.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.4.4.1.Independent Vendor

15.8.4.4.2.Third-party Vendor

15.8.4.5.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.4.5.1.Cardiology

15.8.4.5.2.Orthopedic

15.8.4.5.3.Oncology

15.8.4.5.4.Neurology

15.8.4.5.5.Obstetrics and Gynecology

15.8.4.5.6.Others

15.8.4.6.Germany Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.4.6.1.Hospitals and Clinics

15.8.4.6.2.Diagnostic Centers

15.8.4.6.3.Others

15.8.5.Italy
15.8.5.1.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.5.1.1.CT

15.8.5.1.2.Mammography

15.8.5.1.3.MRI

15.8.5.1.4.Ultrasound

15.8.5.1.5.X-Rays

15.8.5.1.6.PET

15.8.5.2.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.5.2.1.Cloud

15.8.5.2.2.On-Premises

15.8.5.2.3.Hybrid

15.8.5.3.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.5.3.1.VNA
15.8.5.3.1.1.Department VNA

15.8.5.3.1.2.Multi-Department VNA

15.8.5.3.1.3.Multi-Site VNA

15.8.5.3.2.PACS
15.8.5.3.2.1.Department PACS

15.8.5.3.2.2.Multi-Department PACS

15.8.5.3.2.3.Multi-Site PACS

15.8.5.4.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.5.4.1.Independent Vendor

15.8.5.4.2.Third-party Vendor

15.8.5.5.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.5.5.1.Cardiology

15.8.5.5.2.Orthopedic

15.8.5.5.3.Oncology

15.8.5.5.4.Neurology

15.8.5.5.5.Obstetrics and Gynecology

15.8.5.5.6.Others

15.8.5.6.Italy Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.5.6.1.Hospitals and Clinics

15.8.5.6.2.Diagnostic Centers

15.8.5.6.3.Others

15.8.6.Nordic Countries
15.8.6.1.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.6.1.1.CT

15.8.6.1.2.Mammography

15.8.6.1.3.MRI

15.8.6.1.4.Ultrasound

15.8.6.1.5.X-Rays

15.8.6.1.6.PET

15.8.6.2.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.6.2.1.Cloud

15.8.6.2.2.On-Premises

15.8.6.2.3.Hybrid

15.8.6.3.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.6.3.1.VNA
15.8.6.3.1.1.Department VNA

15.8.6.3.1.2.Multi-Department VNA

15.8.6.3.1.3.Multi-Site VNA

15.8.6.3.2.PACS
15.8.6.3.2.1.Department PACS

15.8.6.3.2.2.Multi-Department PACS

15.8.6.3.2.3.Multi-Site PACS

15.8.6.4.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.6.4.1.Independent Vendor

15.8.6.4.2.Third-party Vendor

15.8.6.5.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.6.5.1.Cardiology

15.8.6.5.2.Orthopedic

15.8.6.5.3.Oncology

15.8.6.5.4.Neurology

15.8.6.5.5.Obstetrics and Gynecology

15.8.6.5.6.Others

15.8.6.6.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.6.6.1.Hospitals and Clinics

15.8.6.6.2.Diagnostic Centers

15.8.6.6.3.Others

15.8.6.7.Nordic Countries Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
15.8.6.7.1.Denmark

15.8.6.7.2.Finland

15.8.6.7.3.Iceland

15.8.6.7.4.Sweden

15.8.6.7.5.Norway

15.8.7.Benelux Union
15.8.7.1.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.7.1.1.CT

15.8.7.1.2.Mammography

15.8.7.1.3.MRI

15.8.7.1.4.Ultrasound

15.8.7.1.5.X-Rays

15.8.7.1.6.PET

15.8.7.2.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.7.2.1.Cloud

15.8.7.2.2.On-Premises

15.8.7.2.3.Hybrid

15.8.7.3.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.7.3.1.VNA
15.8.7.3.1.1.Department VNA

15.8.7.3.1.2.Multi-Department VNA

15.8.7.3.1.3.Multi-Site VNA

15.8.7.3.2.PACS
15.8.7.3.2.1.Department PACS

15.8.7.3.2.2.Multi-Department PACS

15.8.7.3.2.3.Multi-Site PACS

15.8.7.4.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.7.4.1.Independent Vendor

15.8.7.4.2.Third-party Vendor

15.8.7.5.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.7.5.1.Cardiology

15.8.7.5.2.Orthopedic

15.8.7.5.3.Oncology

15.8.7.5.4.Neurology

15.8.7.5.5.Obstetrics and Gynecology

15.8.7.5.6.Others

15.8.7.6.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.7.6.1.Hospitals and Clinics

15.8.7.6.2.Diagnostic Centers

15.8.7.6.3.Others

15.8.7.7.Benelux Union Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
15.8.7.7.1.Belgium

15.8.7.7.2.The Netherlands

15.8.7.7.3.Luxembourg

15.8.8.Rest of Europe
15.8.8.1.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
15.8.8.1.1.CT

15.8.8.1.2.Mammography

15.8.8.1.3.MRI

15.8.8.1.4.Ultrasound

15.8.8.1.5.X-Rays

15.8.8.1.6.PET

15.8.8.2.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
15.8.8.2.1.Cloud

15.8.8.2.2.On-Premises

15.8.8.2.3.Hybrid

15.8.8.3.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
15.8.8.3.1.VNA
15.8.8.3.1.1.Department VNA

15.8.8.3.1.2.Multi-Department VNA

15.8.8.3.1.3.Multi-Site VNA

15.8.8.3.2.PACS
15.8.8.3.2.1.Department PACS

15.8.8.3.2.2.Multi-Department PACS

15.8.8.3.2.3.Multi-Site PACS

15.8.8.4.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
15.8.8.4.1.Independent Vendor

15.8.8.4.2.Third-party Vendor

15.8.8.5.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
15.8.8.5.1.Cardiology

15.8.8.5.2.Orthopedic

15.8.8.5.3.Oncology

15.8.8.5.4.Neurology

15.8.8.5.5.Obstetrics and Gynecology

15.8.8.5.6.Others

15.8.8.6.Rest of Europe Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
15.8.8.6.1.Hospitals and Clinics

15.8.8.6.2.Diagnostic Centers

15.8.8.6.3.Others

15.9.Key Segment for Channeling Investments
15.9.1.By Country

15.9.2.By Modality

15.9.3.By Deployment

15.9.4.By Product Type

15.9.5.By Vendor Type

15.9.6.By Application

15.9.7.By End User

16.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
16.1.Overview
16.1.1.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)

16.2.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.2.1.CT

16.2.2.Mammography

16.2.3.MRI

16.2.4.Ultrasound

16.2.5.X-Rays

16.2.6.PET

16.3.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.3.1.Cloud

16.3.2.On-Premises

16.3.3.Hybrid

16.4.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.4.1.VNA
16.4.1.1.Department VNA

16.4.1.2.Multi-Department VNA

16.4.1.3.Multi-Site VNA

16.4.2.PACS
16.4.2.1.Department PACS

16.4.2.2.Multi-Department PACS

16.4.2.3.Multi-Site PACS

16.5.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.5.1.Independent Vendor

16.5.2.Third-party Vendor

16.6.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.Cardiology

16.6.2.Orthopedic

16.6.3.Oncology

16.6.4.Neurology

16.6.5.Obstetrics and Gynecology

16.6.6.Others

16.7.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.7.1.Hospitals and Clinics

16.7.2.Diagnostic Centers

16.7.3.Others

16.8.Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
16.8.1.China
16.8.1.1.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.1.1.1.CT

16.8.1.1.2.Mammography

16.8.1.1.3.MRI

16.8.1.1.4.Ultrasound

16.8.1.1.5.X-Rays

16.8.1.1.6.PET

16.8.1.2.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.1.2.1.Cloud

16.8.1.2.2.On-Premises

16.8.1.2.3.Hybrid

16.8.1.3.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.1.3.1.VNA
16.8.1.3.1.1.Department VNA

16.8.1.3.1.2.Multi-Department VNA

16.8.1.3.1.3.Multi-Site VNA

16.8.1.3.2.PACS
16.8.1.3.2.1.Department PACS

16.8.1.3.2.2.Multi-Department PACS

16.8.1.3.2.3.Multi-Site PACS

16.8.1.4.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.1.4.1.Independent Vendor

16.8.1.4.2.Third-party Vendor

16.8.1.5.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.1.5.1.Cardiology

16.8.1.5.2.Orthopedic

16.8.1.5.3.Oncology

16.8.1.5.4.Neurology

16.8.1.5.5.Obstetrics and Gynecology

16.8.1.5.6.Others

16.8.1.6.China Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.1.6.1.Hospitals and Clinics

16.8.1.6.2.Diagnostic Centers

16.8.1.6.3.Others

16.8.2.Japan
16.8.2.1.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.2.1.1.CT

16.8.2.1.2.Mammography

16.8.2.1.3.MRI

16.8.2.1.4.Ultrasound

16.8.2.1.5.X-Rays

16.8.2.1.6.PET

16.8.2.2.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.2.2.1.Cloud

16.8.2.2.2.On-Premises

16.8.2.2.3.Hybrid

16.8.2.3.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.2.3.1.VNA
16.8.2.3.1.1.Department VNA

16.8.2.3.1.2.Multi-Department VNA

16.8.2.3.1.3.Multi-Site VNA

16.8.2.3.2.PACS
16.8.2.3.2.1.Department PACS

16.8.2.3.2.2.Multi-Department PACS

16.8.2.3.2.3.Multi-Site PACS

16.8.2.4.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.2.4.1.Independent Vendor

16.8.2.4.2.Third-party Vendor

16.8.2.5.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.2.5.1.Cardiology

16.8.2.5.2.Orthopedic

16.8.2.5.3.Oncology

16.8.2.5.4.Neurology

16.8.2.5.5.Obstetrics and Gynecology

16.8.2.5.6.Others

16.8.2.6.Japan Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.2.6.1.Hospitals and Clinics

16.8.2.6.2.Diagnostic Centers

16.8.2.6.3.Others

16.8.3.India
16.8.3.1.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.3.1.1.CT

16.8.3.1.2.Mammography

16.8.3.1.3.MRI

16.8.3.1.4.Ultrasound

16.8.3.1.5.X-Rays

16.8.3.1.6.PET

16.8.3.2.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.3.2.1.Cloud

16.8.3.2.2.On-Premises

16.8.3.2.3.Hybrid

16.8.3.3.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.3.3.1.VNA
16.8.3.3.1.1.Department VNA

16.8.3.3.1.2.Multi-Department VNA

16.8.3.3.1.3.Multi-Site VNA

16.8.3.3.2.PACS
16.8.3.3.2.1.Department PACS

16.8.3.3.2.2.Multi-Department PACS

16.8.3.3.2.3.Multi-Site PACS

16.8.3.4.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.3.4.1.Independent Vendor

16.8.3.4.2.Third-party Vendor

16.8.3.5.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.3.5.1.Cardiology

16.8.3.5.2.Orthopedic

16.8.3.5.3.Oncology

16.8.3.5.4.Neurology

16.8.3.5.5.Obstetrics and Gynecology

16.8.3.5.6.Others

16.8.3.6.India Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.3.6.1.Hospitals and Clinics

16.8.3.6.2.Diagnostic Centers

16.8.3.6.3.Others

16.8.4.New Zealand
16.8.4.1.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.4.1.1.CT

16.8.4.1.2.Mammography

16.8.4.1.3.MRI

16.8.4.1.4.Ultrasound

16.8.4.1.5.X-Rays

16.8.4.1.6.PET

16.8.4.2.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.4.2.1.Cloud

16.8.4.2.2.On-Premises

16.8.4.2.3.Hybrid

16.8.4.3.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.4.3.1.VNA
16.8.4.3.1.1.Department VNA

16.8.4.3.1.2.Multi-Department VNA

16.8.4.3.1.3.Multi-Site VNA

16.8.4.3.2.PACS
16.8.4.3.2.1.Department PACS

16.8.4.3.2.2.Multi-Department PACS

16.8.4.3.2.3.Multi-Site PACS

16.8.4.4.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.4.4.1.Independent Vendor

16.8.4.4.2.Third-party Vendor

16.8.4.5.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.4.5.1.Cardiology

16.8.4.5.2.Orthopedic

16.8.4.5.3.Oncology

16.8.4.5.4.Neurology

16.8.4.5.5.Obstetrics and Gynecology

16.8.4.5.6.Others

16.8.4.6.New Zealand Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.4.6.1.Hospitals and Clinics

16.8.4.6.2.Diagnostic Centers

16.8.4.6.3.Others

16.8.5.Australia
16.8.5.1.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.5.1.1.CT

16.8.5.1.2.Mammography

16.8.5.1.3.MRI

16.8.5.1.4.Ultrasound

16.8.5.1.5.X-Rays

16.8.5.1.6.PET

16.8.5.2.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.5.2.1.Cloud

16.8.5.2.2.On-Premises

16.8.5.2.3.Hybrid

16.8.5.3.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.5.3.1.VNA
16.8.5.3.1.1.Department VNA

16.8.5.3.1.2.Multi-Department VNA

16.8.5.3.1.3.Multi-Site VNA

16.8.5.3.2.PACS
16.8.5.3.2.1.Department PACS

16.8.5.3.2.2.Multi-Department PACS

16.8.5.3.2.3.Multi-Site PACS

16.8.5.4.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.5.4.1.Independent Vendor

16.8.5.4.2.Third-party Vendor

16.8.5.5.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.5.5.1.Cardiology

16.8.5.5.2.Orthopedic

16.8.5.5.3.Oncology

16.8.5.5.4.Neurology

16.8.5.5.5.Obstetrics and Gynecology

16.8.5.5.6.Others

16.8.5.6.Australia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.5.6.1.Hospitals and Clinics

16.8.5.6.2.Diagnostic Centers

16.8.5.6.3.Others

16.8.6.South Korea
16.8.6.1.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.6.1.1.CT

16.8.6.1.2.Mammography

16.8.6.1.3.MRI

16.8.6.1.4.Ultrasound

16.8.6.1.5.X-Rays

16.8.6.1.6.PET

16.8.6.2.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.6.2.1.Cloud

16.8.6.2.2.On-Premises

16.8.6.2.3.Hybrid

16.8.6.3.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.6.3.1.VNA
16.8.6.3.1.1.Department VNA

16.8.6.3.1.2.Multi-Department VNA

16.8.6.3.1.3.Multi-Site VNA

16.8.6.3.2.PACS
16.8.6.3.2.1.Department PACS

16.8.6.3.2.2.Multi-Department PACS

16.8.6.3.2.3.Multi-Site PACS

16.8.6.4.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.6.4.1.Independent Vendor

16.8.6.4.2.Third-party Vendor

16.8.6.5.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.6.5.1.Cardiology

16.8.6.5.2.Orthopedic

16.8.6.5.3.Oncology

16.8.6.5.4.Neurology

16.8.6.5.5.Obstetrics and Gynecology

16.8.6.5.6.Others

16.8.6.6.South Korea Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.6.6.1.Hospitals and Clinics

16.8.6.6.2.Diagnostic Centers

16.8.6.6.3.Others

16.8.7.Southeast Asia
16.8.7.1.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.7.1.1.CT

16.8.7.1.2.Mammography

16.8.7.1.3.MRI

16.8.7.1.4.Ultrasound

16.8.7.1.5.X-Rays

16.8.7.1.6.PET

16.8.7.2.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.7.2.1.Cloud

16.8.7.2.2.On-Premises

16.8.7.2.3.Hybrid

16.8.7.3.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.7.3.1.VNA
16.8.7.3.1.1.Department VNA

16.8.7.3.1.2.Multi-Department VNA

16.8.7.3.1.3.Multi-Site VNA

16.8.7.3.2.PACS
16.8.7.3.2.1.Department PACS

16.8.7.3.2.2.Multi-Department PACS

16.8.7.3.2.3.Multi-Site PACS

16.8.7.4.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.7.4.1.Independent Vendor

16.8.7.4.2.Third-party Vendor

16.8.7.5.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.7.5.1.Cardiology

16.8.7.5.2.Orthopedic

16.8.7.5.3.Oncology

16.8.7.5.4.Neurology

16.8.7.5.5.Obstetrics and Gynecology

16.8.7.5.6.Others

16.8.7.6.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.7.6.1.Hospitals and Clinics

16.8.7.6.2.Diagnostic Centers

16.8.7.6.3.Others

16.8.7.7.Southeast Asia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
16.8.7.7.1.Indonesia

16.8.7.7.2.Thailand

16.8.7.7.3.Malaysia

16.8.7.7.4.Singapore

16.8.7.7.5.Rest of Southeast Asia

16.8.8.Rest of Asia Pacific
16.8.8.1.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
16.8.8.1.1.CT

16.8.8.1.2.Mammography

16.8.8.1.3.MRI

16.8.8.1.4.Ultrasound

16.8.8.1.5.X-Rays

16.8.8.1.6.PET

16.8.8.2.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
16.8.8.2.1.Cloud

16.8.8.2.2.On-Premises

16.8.8.2.3.Hybrid

16.8.8.3.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
16.8.8.3.1.VNA
16.8.8.3.1.1.Department VNA

16.8.8.3.1.2.Multi-Department VNA

16.8.8.3.1.3.Multi-Site VNA

16.8.8.3.2.PACS
16.8.8.3.2.1.Department PACS

16.8.8.3.2.2.Multi-Department PACS

16.8.8.3.2.3.Multi-Site PACS

16.8.8.4.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
16.8.8.4.1.Independent Vendor

16.8.8.4.2.Third-party Vendor

16.8.8.5.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
16.8.8.5.1.Cardiology

16.8.8.5.2.Orthopedic

16.8.8.5.3.Oncology

16.8.8.5.4.Neurology

16.8.8.5.5.Obstetrics and Gynecology

16.8.8.5.6.Others

16.8.8.6.Rest of Asia Pacific Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
16.8.8.6.1.Hospitals and Clinics

16.8.8.6.2.Diagnostic Centers

16.8.8.6.3.Others

16.9.Key Segment for Channeling Investments
16.9.1.By Country

16.9.2.By Modality

16.9.3.By Deployment

16.9.4.By Product Type

16.9.5.By Vendor Type

16.9.6.By Application

16.9.7.By End User

17.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
17.1.Overview
17.1.1.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)

17.2.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.2.1.CT

17.2.2.Mammography

17.2.3.MRI

17.2.4.Ultrasound

17.2.5.X-Rays

17.2.6.PET

17.3.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.3.1.Cloud

17.3.2.On-Premises

17.3.3.Hybrid

17.4.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.4.1.VNA
17.4.1.1.Department VNA

17.4.1.2.Multi-Department VNA

17.4.1.3.Multi-Site VNA

17.4.2.PACS
17.4.2.1.Department PACS

17.4.2.2.Multi-Department PACS

17.4.2.3.Multi-Site PACS

17.5.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.5.1.Independent Vendor

17.5.2.Third-party Vendor

17.6.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.6.1.Cardiology

17.6.2.Orthopedic

17.6.3.Oncology

17.6.4.Neurology

17.6.5.Obstetrics and Gynecology

17.6.6.Others

17.7.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.7.1.Hospitals and Clinics

17.7.2.Diagnostic Centers

17.7.3.Others

17.8.Middle East and Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
17.8.1.Saudi Arabia
17.8.1.1.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.1.1.1.CT

17.8.1.1.2.Mammography

17.8.1.1.3.MRI

17.8.1.1.4.Ultrasound

17.8.1.1.5.X-Rays

17.8.1.1.6.PET

17.8.1.2.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.1.2.1.Cloud

17.8.1.2.2.On-Premises

17.8.1.2.3.Hybrid

17.8.1.3.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.1.3.1.VNA
17.8.1.3.1.1.Department VNA

17.8.1.3.1.2.Multi-Department VNA

17.8.1.3.1.3.Multi-Site VNA

17.8.1.3.2.PACS
17.8.1.3.2.1.Department PACS

17.8.1.3.2.2.Multi-Department PACS

17.8.1.3.2.3.Multi-Site PACS

17.8.1.4.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.1.4.1.Independent Vendor

17.8.1.4.2.Third-party Vendor

17.8.1.5.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.1.5.1.Cardiology

17.8.1.5.2.Orthopedic

17.8.1.5.3.Oncology

17.8.1.5.4.Neurology

17.8.1.5.5.Obstetrics and Gynecology

17.8.1.5.6.Others

17.8.1.6.Saudi Arabia Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.1.6.1.Hospitals and Clinics

17.8.1.6.2.Diagnostic Centers

17.8.1.6.3.Others

17.8.2.UAE
17.8.2.1.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.2.1.1.CT

17.8.2.1.2.Mammography

17.8.2.1.3.MRI

17.8.2.1.4.Ultrasound

17.8.2.1.5.X-Rays

17.8.2.1.6.PET

17.8.2.2.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.2.2.1.Cloud

17.8.2.2.2.On-Premises

17.8.2.2.3.Hybrid

17.8.2.3.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.2.3.1.VNA
17.8.2.3.1.1.Department VNA

17.8.2.3.1.2.Multi-Department VNA

17.8.2.3.1.3.Multi-Site VNA

17.8.2.3.2.PACS
17.8.2.3.2.1.Department PACS

17.8.2.3.2.2.Multi-Department PACS

17.8.2.3.2.3.Multi-Site PACS

17.8.2.4.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.2.4.1.Independent Vendor

17.8.2.4.2.Third-party Vendor

17.8.2.5.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.2.5.1.Cardiology

17.8.2.5.2.Orthopedic

17.8.2.5.3.Oncology

17.8.2.5.4.Neurology

17.8.2.5.5.Obstetrics and Gynecology

17.8.2.5.6.Others

17.8.2.6.UAE Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.2.6.1.Hospitals and Clinics

17.8.2.6.2.Diagnostic Centers

17.8.2.6.3.Others

17.8.3.Egypt
17.8.3.1.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.3.1.1.CT

17.8.3.1.2.Mammography

17.8.3.1.3.MRI

17.8.3.1.4.Ultrasound

17.8.3.1.5.X-Rays

17.8.3.1.6.PET

17.8.3.2.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.3.2.1.Cloud

17.8.3.2.2.On-Premises

17.8.3.2.3.Hybrid

17.8.3.3.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.3.3.1.VNA
17.8.3.3.1.1.Department VNA

17.8.3.3.1.2.Multi-Department VNA

17.8.3.3.1.3.Multi-Site VNA

17.8.3.3.2.PACS
17.8.3.3.2.1.Department PACS

17.8.3.3.2.2.Multi-Department PACS

17.8.3.3.2.3.Multi-Site PACS

17.8.3.4.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.3.4.1.Independent Vendor

17.8.3.4.2.Third-party Vendor

17.8.3.5.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.3.5.1.Cardiology

17.8.3.5.2.Orthopedic

17.8.3.5.3.Oncology

17.8.3.5.4.Neurology

17.8.3.5.5.Obstetrics and Gynecology

17.8.3.5.6.Others

17.8.3.6.Egypt Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.3.6.1.Hospitals and Clinics

17.8.3.6.2.Diagnostic Centers

17.8.3.6.3.Others

17.8.4.Kuwait
17.8.4.1.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.4.1.1.CT

17.8.4.1.2.Mammography

17.8.4.1.3.MRI

17.8.4.1.4.Ultrasound

17.8.4.1.5.X-Rays

17.8.4.1.6.PET

17.8.4.2.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.4.2.1.Cloud

17.8.4.2.2.On-Premises

17.8.4.2.3.Hybrid

17.8.4.3.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.4.3.1.VNA
17.8.4.3.1.1.Department VNA

17.8.4.3.1.2.Multi-Department VNA

17.8.4.3.1.3.Multi-Site VNA

17.8.4.3.2.PACS
17.8.4.3.2.1.Department PACS

17.8.4.3.2.2.Multi-Department PACS

17.8.4.3.2.3.Multi-Site PACS

17.8.4.4.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.4.4.1.Independent Vendor

17.8.4.4.2.Third-party Vendor

17.8.4.5.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.4.5.1.Cardiology

17.8.4.5.2.Orthopedic

17.8.4.5.3.Oncology

17.8.4.5.4.Neurology

17.8.4.5.5.Obstetrics and Gynecology

17.8.4.5.6.Others

17.8.4.6.Kuwait Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.4.6.1.Hospitals and Clinics

17.8.4.6.2.Diagnostic Centers

17.8.4.6.3.Others

17.8.5.South Africa
17.8.5.1.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.5.1.1.CT

17.8.5.1.2.Mammography

17.8.5.1.3.MRI

17.8.5.1.4.Ultrasound

17.8.5.1.5.X-Rays

17.8.5.1.6.PET

17.8.5.2.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.5.2.1.Cloud

17.8.5.2.2.On-Premises

17.8.5.2.3.Hybrid

17.8.5.3.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.5.3.1.VNA
17.8.5.3.1.1.Department VNA

17.8.5.3.1.2.Multi-Department VNA

17.8.5.3.1.3.Multi-Site VNA

17.8.5.3.2.PACS
17.8.5.3.2.1.Department PACS

17.8.5.3.2.2.Multi-Department PACS

17.8.5.3.2.3.Multi-Site PACS

17.8.5.4.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.5.4.1.Independent Vendor

17.8.5.4.2.Third-party Vendor

17.8.5.5.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.5.5.1.Cardiology

17.8.5.5.2.Orthopedic

17.8.5.5.3.Oncology

17.8.5.5.4.Neurology

17.8.5.5.5.Obstetrics and Gynecology

17.8.5.5.6.Others

17.8.5.6.South Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.5.6.1.Hospitals and Clinics

17.8.5.6.2.Diagnostic Centers

17.8.5.6.3.Others

17.8.6.Rest of Middle East & Africa
17.8.6.1.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
17.8.6.1.1.CT

17.8.6.1.2.Mammography

17.8.6.1.3.MRI

17.8.6.1.4.Ultrasound

17.8.6.1.5.X-Rays

17.8.6.1.6.PET

17.8.6.2.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
17.8.6.2.1.Cloud

17.8.6.2.2.On-Premises

17.8.6.2.3.Hybrid

17.8.6.3.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
17.8.6.3.1.VNA
17.8.6.3.1.1.Department VNA

17.8.6.3.1.2.Multi-Department VNA

17.8.6.3.1.3.Multi-Site VNA

17.8.6.3.2.PACS
17.8.6.3.2.1.Department PACS

17.8.6.3.2.2.Multi-Department PACS

17.8.6.3.2.3.Multi-Site PACS

17.8.6.4.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
17.8.6.4.1.Independent Vendor

17.8.6.4.2.Third-party Vendor

17.8.6.5.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
17.8.6.5.1.Cardiology

17.8.6.5.2.Orthopedic

17.8.6.5.3.Oncology

17.8.6.5.4.Neurology

17.8.6.5.5.Obstetrics and Gynecology

17.8.6.5.6.Others

17.8.6.6.Rest of Middle East & Africa Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
17.8.6.6.1.Hospitals and Clinics

17.8.6.6.2.Diagnostic Centers

17.8.6.6.3.Others

17.9.Key Segment for Channeling Investments
17.9.1.By Country

17.9.2.By Modality

17.9.3.By Deployment

17.9.4.By Product Type

17.9.5.By Vendor Type

17.9.6.By Application

17.9.7.By End User

18.Latin America Vendor Neutral Archive (VNA) and PACS Market Analysis and Forecasts, 2024 – 2034
18.1.Overview
18.1.1.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn)

18.2.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
18.2.1.CT

18.2.2.Mammography

18.2.3.MRI

18.2.4.Ultrasound

18.2.5.X-Rays

18.2.6.PET

18.3.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
18.3.1.Cloud

18.3.2.On-Premises

18.3.3.Hybrid

18.4.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
18.4.1.VNA
18.4.1.1.Department VNA

18.4.1.2.Multi-Department VNA

18.4.1.3.Multi-Site VNA

18.4.2.PACS
18.4.2.1.Department PACS

18.4.2.2.Multi-Department PACS

18.4.2.3.Multi-Site PACS

18.5.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
18.5.1.Independent Vendor

18.5.2.Third-party Vendor

18.6.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
18.6.1.Cardiology

18.6.2.Orthopedic

18.6.3.Oncology

18.6.4.Neurology

18.6.5.Obstetrics and Gynecology

18.6.6.Others

18.7.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
18.7.1.Hospitals and Clinics

18.7.2.Diagnostic Centers

18.7.3.Others

18.8.Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Country
18.8.1.Brazil
18.8.1.1.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
18.8.1.1.1.CT

18.8.1.1.2.Mammography

18.8.1.1.3.MRI

18.8.1.1.4.Ultrasound

18.8.1.1.5.X-Rays

18.8.1.1.6.PET

18.8.1.2.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
18.8.1.2.1.Cloud

18.8.1.2.2.On-Premises

18.8.1.2.3.Hybrid

18.8.1.3.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
18.8.1.3.1.VNA
18.8.1.3.1.1.Department VNA

18.8.1.3.1.2.Multi-Department VNA

18.8.1.3.1.3.Multi-Site VNA

18.8.1.3.2.PACS
18.8.1.3.2.1.Department PACS

18.8.1.3.2.2.Multi-Department PACS

18.8.1.3.2.3.Multi-Site PACS

18.8.1.4.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
18.8.1.4.1.Independent Vendor

18.8.1.4.2.Third-party Vendor

18.8.1.5.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
18.8.1.5.1.Cardiology

18.8.1.5.2.Orthopedic

18.8.1.5.3.Oncology

18.8.1.5.4.Neurology

18.8.1.5.5.Obstetrics and Gynecology

18.8.1.5.6.Others

18.8.1.6.Brazil Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
18.8.1.6.1.Hospitals and Clinics

18.8.1.6.2.Diagnostic Centers

18.8.1.6.3.Others

18.8.2.Argentina
18.8.2.1.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
18.8.2.1.1.CT

18.8.2.1.2.Mammography

18.8.2.1.3.MRI

18.8.2.1.4.Ultrasound

18.8.2.1.5.X-Rays

18.8.2.1.6.PET

18.8.2.2.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
18.8.2.2.1.Cloud

18.8.2.2.2.On-Premises

18.8.2.2.3.Hybrid

18.8.2.3.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
18.8.2.3.1.VNA
18.8.2.3.1.1.Department VNA

18.8.2.3.1.2.Multi-Department VNA

18.8.2.3.1.3.Multi-Site VNA

18.8.2.3.2.PACS
18.8.2.3.2.1.Department PACS

18.8.2.3.2.2.Multi-Department PACS

18.8.2.3.2.3.Multi-Site PACS

18.8.2.4.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
18.8.2.4.1.Independent Vendor

18.8.2.4.2.Third-party Vendor

18.8.2.5.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
18.8.2.5.1.Cardiology

18.8.2.5.2.Orthopedic

18.8.2.5.3.Oncology

18.8.2.5.4.Neurology

18.8.2.5.5.Obstetrics and Gynecology

18.8.2.5.6.Others

18.8.2.6.Argentina Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
18.8.2.6.1.Hospitals and Clinics

18.8.2.6.2.Diagnostic Centers

18.8.2.6.3.Others

18.8.3.Rest of Latin America
18.8.3.1.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Modality
18.8.3.1.1.CT

18.8.3.1.2.Mammography

18.8.3.1.3.MRI

18.8.3.1.4.Ultrasound

18.8.3.1.5.X-Rays

18.8.3.1.6.PET

18.8.3.2.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Deployment
18.8.3.2.1.Cloud

18.8.3.2.2.On-Premises

18.8.3.2.3.Hybrid

18.8.3.3.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Product Type
18.8.3.3.1.VNA
18.8.3.3.1.1.Department VNA

18.8.3.3.1.2.Multi-Department VNA

18.8.3.3.1.3.Multi-Site VNA

18.8.3.3.2.PACS
18.8.3.3.2.1.Department PACS

18.8.3.3.2.2.Multi-Department PACS

18.8.3.3.2.3.Multi-Site PACS

18.8.3.4.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Vendor Type
18.8.3.4.1.Independent Vendor

18.8.3.4.2.Third-party Vendor

18.8.3.5.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By Application
18.8.3.5.1.Cardiology

18.8.3.5.2.Orthopedic

18.8.3.5.3.Oncology

18.8.3.5.4.Neurology

18.8.3.5.5.Obstetrics and Gynecology

18.8.3.5.6.Others

18.8.3.6.Rest of Latin America Vendor Neutral Archive (VNA) and PACS Market Revenue (US$ Mn) and Forecasts, By End User
18.8.3.6.1.Hospitals and Clinics

18.8.3.6.2.Diagnostic Centers

18.8.3.6.3.Others

18.9.Key Segment for Channeling Investments
18.9.1.By Country

18.9.2.By Modality

18.9.3.By Deployment

18.9.4.By Product Type

18.9.5.By Vendor Type

18.9.6.By Application

18.9.7.By End User

19.Competitive Benchmarking
19.1.Brand Benchmarking

19.2.Market Share Analysis, 2023

19.3.Global Presence and Growth Strategies
19.3.1.Mergers and Acquisitions

19.3.2.Product Launches

19.3.3.Investments Trends

19.3.4.R&D Initiatives

20.Player Profiles
20.1.Agfa Healthcare NV
20.1.1.Company Details

20.1.2.Company Overview

20.1.3.Product Offerings

20.1.4.Key Developments

20.1.5.Financial Analysis

20.1.6.SWOT Analysis

20.1.7.Business Strategies

20.2.Dell Technologies Inc.
20.2.1.Company Details

20.2.2.Company Overview

20.2.3.Product Offerings

20.2.4.Key Developments

20.2.5.Financial Analysis

20.2.6.SWOT Analysis

20.2.7.Business Strategies

20.3.FUJIFILM Holdings Corporation
20.3.1.Company Details

20.3.2.Company Overview

20.3.3.Product Offerings

20.3.4.Key Developments

20.3.5.Financial Analysis

20.3.6.SWOT Analysis

20.3.7.Business Strategies

20.4.GE Healthcare
20.4.1.Company Details

20.4.2.Company Overview

20.4.3.Product Offerings

20.4.4.Key Developments

20.4.5.Financial Analysis

20.4.6.SWOT Analysis

20.4.7.Business Strategies

20.5.IBM Corporation
20.5.1.Company Details

20.5.2.Company Overview

20.5.3.Product Offerings

20.5.4.Key Developments

20.5.5.Financial Analysis

20.5.6.SWOT Analysis

20.5.7.Business Strategies

20.6.Koninklijke Philips NV
20.6.1.Company Details

20.6.2.Company Overview

20.6.3.Product Offerings

20.6.4.Key Developments

20.6.5.Financial Analysis

20.6.6.SWOT Analysis

20.6.7.Business Strategies

20.7.Lexmark International Inc.
20.7.1.Company Details

20.7.2.Company Overview

20.7.3.Product Offerings

20.7.4.Key Developments

20.7.5.Financial Analysis

20.7.6.SWOT Analysis

20.7.7.Business Strategies

20.8.McKesson Corporation
20.8.1.Company Details

20.8.2.Company Overview

20.8.3.Product Offerings

20.8.4.Key Developments

20.8.5.Financial Analysis

20.8.6.SWOT Analysis

20.8.7.Business Strategies

20.9.Novarad Corporation
20.9.1.Company Details

20.9.2.Company Overview

20.9.3.Product Offerings

20.9.4.Key Developments

20.9.5.Financial Analysis

20.9.6.SWOT Analysis

20.9.7.Business Strategies

20.10.Siemens Healthineers AG
20.10.1.Company Details

20.10.2.Company Overview

20.10.3.Product Offerings

20.10.4.Key Developments

20.10.5.Financial Analysis

20.10.6.SWOT Analysis

20.10.7.Business Strategies

20.11.Other Market Participants

21.Key Findings

.

**Exclusive for Multi-User and Enterprise User.

Global Vendor Neutral Archive (VNA) & PACS Market

By Modality

  • CT
  • Mammography
  • MRI
  • Ultrasound
  • X-Rays
  • PET

By Deployment

  • On-Premise
  • Cloud-Based
  • Hybrid Model

By Product Type

  • VNA
    • Department VNA
    • Multi-Department VNA
    • Multi-Site VNA
  • PACS
    • Department PACS
    • Multi-Department PACS
    • Multi-Site PACS

By Vendor Type

  • Independent Vendor
  • Third-party Vendor

By Application

  • Cardiology
  • Orthopedic
  • Oncology
  • Neurology
  • Obstetrics and Gynecology
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers.

Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues.

Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts.

Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here’s a breakdown of our data validation processes and the stakeholders we engage with during our primary research:

  • Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
  • Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
  • Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
  • In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.

The forecasts we provide are based on a comprehensive assessment of various factors, including:

  • Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market’s evolution.
  • Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
  • Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
  • Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
  • New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
  • Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
  • End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
  • Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
  • Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market’s historical performance.

Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It’s crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.

 

 

Procure Comprehensive Study of

Global Vendor Neutral Archive (VNA) & PACS Market

Online Only

  • Online Access
  • Read Only File
  • Validity 3 Months
  • Print, Copy, Paste & Download
  • PPT, Excel
  • Cost-Free Report in the Next Update
$3300
Buy Now

Single User

  • Access to One User on One System
  • Read Only File
  • Validity 6 Months
  • Limited Print,Copy, Paste
  • PPT, Excel
  • Cost-Free Report in the Next Update
$4200
Buy Now

Multi User

  • Access to Fiver Users
  • PDF File
  • Validity 1 Year
  • Upto FivePrints
  • Cost-Free Report in the Next Update
  • PPT, Excel
$6000
Buy Now

Enterprise User

  • Access to Unlimited Users
  • PDF, PPT, Excel
  • Unlimited Validity, Prints&Downloads
  • 1 Hour Cost-Free & Dedicated Analyst Support
  • 10% Cost-Free Customization
  • Cost-Free Report Update Twice in a Year
  • Recommendations for Business Strategies
  • Authorization to Quote TNR, The Niche Research
$7300
Buy Now

Library Access

  • Online Access to Content Publications
  • Access Player Profiles Online
  • Get Immediate Access to Newly Added Content
  • Acquire 12 PDF Downloads
  • Acquire 5 Excel Data Sets
  • Gain Access to 290+ PDFs of Company Profiles
  • Round-the-clock Email and Phone Assistance
  • Dashboard Usage and Trends
  • Renewal & Upgrade Assistance
  • Assessing Customization Options and Alerts for New Reports
$10788
Buy Now
*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Why TNR The Niche Research?

  • Unwavering Commitment to Excellence

  • Veteran Team of Researchers

  • Accurate and Timely Insights

  • Ethical Practices and Customized Service

  • Uninterrupted Availability Around the Clock

Scroll to Top